Demetrios Doukas, DO
Interventional Cardiology · Maywood, ILNPI 1801161906
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (48.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 64.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2020 at $15,160 and has fallen 59.1% since, to $6,204 in 2025.
Across 304 payments — averaging $102.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$20K
- Abbott$8K
- Biotronik Inc.$1K
- Cardiovascular Systems Inc.$371
- Johnson & Johnson$270
- Boston Scientific$255
- plus $979 from 12 others
Across 16 payments — averaging $6498.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$101K
- Abbott$3K
What the payments were for
- Speaking & faculty fees$3,00010%
- Grants$15,00048%
- Travel & lodging$3,64712%
- Food & beverage$9,25530%
- Education$1400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 83 | $20,121 |
| Abbott | 127 | $7,898 |
| Biotronik Inc. | 39 | $1,149 |
| Cardiovascular Systems Inc. | 5 | $371 |
| Johnson & Johnson | 7 | $270 |
| Boston Scientific | 6 | $255 |
| Shockwave Medical, Inc | 17 | $220 |
| Abiomed | 5 | $160 |
| Edwards Lifesciences | 4 | $153 |
| AstraZeneca | 1 | $125 |
| Tempus AI, Inc | 1 | $122 |
| Actelion Pharmaceuticals US, Inc. | 2 | $56 |
| Surmodics, Inc. | 2 | $38 |
| Novartis | 1 | $31 |
| Getinge USA Sales, LLC | 1 | $23 |
| Cook Medical LLC | 1 | $20 |
| Amgen | 1 | $20 |
| W. L. Gore & Associates, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$3,123
- COREVALVE EVOLUT R$2,958
- MitraClip$2,094
- Orsiro Mission$328
- CoreValve Evolut$309
- PRO-Kinetic Energy$304
- PK Papyrus$304
- XARELTO$226
- Diamondback Coronary$218
- ENSITE PRECISION$163
- Astron; Pulsar; AstronPulsar$154
- Orsiro$154
- Pulsar$154
- Passeo-18$150
- Integrity$140
- WATCHMAN Access System$135
- Dragonfly OCT$135
- Optis Coronary Imaging System$129
- OPTIS$127
- BRILINTA$125
How this compares
$31,042 in reported general payments places this provider in the 80th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 55 | $63,937 |
| XareltoRivaroxaban | 19 | $28,768 |
| Repatha SureclickEvolocumab | 30 | $26,872 |
| FarxigaDapagliflozin Propanediol | 16 | $17,389 |
| JardianceEmpagliflozin | 13 | $15,804 |
| Metoprolol Succinate | 199 | $2,851 |
| Atorvastatin Calcium | 279 | $2,699 |
| VascepaIcosapent Ethyl | 13 | $2,605 |
| ClopidogrelClopidogrel Bisulfate | 157 | $2,167 |
| Ezetimibe | 60 | $1,731 |
| Amlodipine Besylate | 137 | $1,372 |
| Rosuvastatin Calcium | 39 | $989 |
| Bumetanide | 25 | $957 |
| Potassium Chloride | 35 | $921 |
| Losartan Potassium | 76 | $863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $270 | $28,76819 claims |
| AstraZenecaFarxiga | $125 | $17,38916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Maywood
- Bruce LewisMaywood$83K
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
- David StewartChicago$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.